Jennifer has over 25 years of comprehensive experience across all areas of clinical operations. While her career began in late development, the past 12 years have been focused on early development, where she has successfully led portfolios from first-in-human through proof-of-concept studies. Jennifer views each study as an opportunity to craft and execute the most effective operational strategy.

Before joining Third Arc Bio, Jennifer served as Vice President of Clinical Operations at Scorpion Therapeutics and was previously a Senior Director at IMV, Inc. She also spent eight years at Johnson & Johnson (J&J), where she led global programs in Early Development Oncology and Immunology, working on over 20 drugs across multiple indications and modalities. Earlier in her career, Jennifer held roles at Roche, Shire, AstraZeneca, and Merck.

Jennifer earned a BA in Psychology from Yale University.